Janssen to Move forward with Clinical Development of LAVA Therapeutics’s Lead Gamma-Delta T-Cell Engager Bispecific Antibody

(24/7 MARKET NEWS) – LAVA Therapeutics N.V. (Nasdaq: LVTX) stated, after yesterday’s market close, that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has chosen a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.

LAVA Therapeutics is trading at $2.37, up $0.47 (+24.73%), on 720.85K premarket shares traded.

Its 52-week range is $1.365 to $7.38. If its trading volume increases, it’s close to breaking the resistance between here and February’s $3.50-$4 range.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist